health

February 27, 2026

There's a 'bearish-to-bullish' reversal happening in this mid-cap biotech stock, says Carter Worth

Carter Worth takes a look at the charts for mid-cap biotech Immunovant.

There's a 'bearish-to-bullish' reversal happening in this mid-cap biotech stock, says Carter Worth

TL;DR

  • Immunovant stock is considered well-positioned for a move higher.
  • The stock is undergoing a 'bearish-to-bullish' reversal.
  • It exhibits bullish price-volume correlation.
  • Immunovant shows impressive relative strength compared to the market and other biotech stocks.
  • The recommendation is to buy the stock.
  • The price objective is set at $40+/-.

Continue reading the original article

Made withNostr